ARDELYX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.42 USD | +1.74% |
|
-0.93% | +3.55% |
| 04-17 | Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating | MT |
| 04-05 | Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target | MT |
| Sales 2024 * | 209M 16.72B | Sales 2025 * | 367M 29.38B | Capitalization | 1.49B 120B |
|---|---|---|---|---|---|
| Net income 2024 * | -107M -8.57B | Net income 2025 * | 6M 480M | EV / Sales 2024 * | 7.15 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.07 x |
| P/E ratio 2024 * |
-14.3
x | P/E ratio 2025 * |
233
x | Employees | 267 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ardelyx, Inc.
More recommendations
More press releases
| 1 day | +1.74% | ||
| 1 week | -0.93% | ||
| Current month | -12.05% | ||
| 1 month | -13.48% | ||
| 3 months | -29.14% | ||
| 6 months | +78.33% | ||
| Current year | +3.55% |
1 week
6.23
6.72
1 month
6.237.87
Current year
5.9210.13
1 year
3.1610.13
3 years
0.4910.13
5 years
0.4910.13
10 years
0.4935.48
| Managers | Title | Age | Since |
|---|---|---|---|
Mike Raab Raab
CEO | Chief Executive Officer | 59 | 28/02/09 |
Justin Renz
DFI | Director of Finance/CFO | 52 | 08/06/20 |
Laura Williams
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/10/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Bertrand
BRD | Director/Board Member | 59 | 25/10/15 |
Richard Rodgers
BRD | Director/Board Member | 57 | 28/02/14 |
David Mott
CHM | Chairman | 58 | 28/02/09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 773 M€ | -.--% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 6.42 | +1.74% | 5,484,539 |
| 25/04/24 | 6.31 | -1.87% | 5,171,676 |
| 24/04/24 | 6.43 | +0.63% | 5,456,420 |
| 23/04/24 | 6.39 | -1.84% | 3,833,064 |
| 22/04/24 | 6.51 | +0.46% | 4,582,376 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Calendar
01/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
6.42
USD
Average target price
13.5
USD
Spread / Average Target
+110.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.55% | 1.49B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ARDX Stock
